Determining the effect of highly active antiretroviral therapy on changes in human immunodeficiency virus type 1 RNA viral load using a marginal structural left-censored mean model

Stephen R. Cole, Miguel A. Hernán, Kathryn Anastos, Beth D. Jamieson, James M. Robins

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Highly active antiretroviral therapy (HAART) dramatically reduces the load of circulating human immunodeficiency virus type 1 (HIV-1) by blocking replication at multiple points in the viral life cycle, but the long-term effect of HAART on viral load remains unclear. In the Multicenter AIDS Cohort Study and the Women's Interagency HIV Study, 918 HIV-1-infected men and women who were not using antiretroviral therapy were followed for a median of 5.8 years between 1996 and 2005. Follow-up yielded 3,629 person-years of observation, during which 286 (31%) of the participants initiated HAART. A marginal structural left-censored linear model for semiannual repeated assessments of viral load showed a 1.9 log10 decrease in viral load after HAART initiation as compared with nonuse (95% confidence interval: 1.7, 2.2), which remained stable over the course of follow-up but was stronger among men (interaction p < 0.001). This association was attenuated by 10% when the authors ignored the left-censoring of viral load measurements (which comprised 20% of measurements (1,420/7,258)) and attenuated by 57% when the authors adjusted for time-varying covariates in a standard fashion rather than using the marginal structural model. In conclusion, the clinically important protective effect of HAART on dampening viral load appears to be rapid, present at CD4 cell counts greater than 350 cells/mm3, and sustained beyond 6 years.

Original languageEnglish (US)
Pages (from-to)219-227
Number of pages9
JournalAmerican Journal of Epidemiology
Volume166
Issue number2
DOIs
StatePublished - Jun 2007

Fingerprint

Highly Active Antiretroviral Therapy
Viral Load
HIV-1
RNA
Structural Models
CD4 Lymphocyte Count
Life Cycle Stages
Linear Models
Acquired Immunodeficiency Syndrome
Cohort Studies
Observation
HIV
Confidence Intervals

Keywords

  • Acquired immunodeficiency syndrome
  • Antiretroviral therapy, highly active
  • Bias (epidemiology)
  • Causality
  • Confounding factors (epidemiology)
  • HIV-1
  • Viral load

ASJC Scopus subject areas

  • Epidemiology

Cite this

Determining the effect of highly active antiretroviral therapy on changes in human immunodeficiency virus type 1 RNA viral load using a marginal structural left-censored mean model. / Cole, Stephen R.; Hernán, Miguel A.; Anastos, Kathryn; Jamieson, Beth D.; Robins, James M.

In: American Journal of Epidemiology, Vol. 166, No. 2, 06.2007, p. 219-227.

Research output: Contribution to journalArticle

@article{3e7241379d51443683a221d12836dc9e,
title = "Determining the effect of highly active antiretroviral therapy on changes in human immunodeficiency virus type 1 RNA viral load using a marginal structural left-censored mean model",
abstract = "Highly active antiretroviral therapy (HAART) dramatically reduces the load of circulating human immunodeficiency virus type 1 (HIV-1) by blocking replication at multiple points in the viral life cycle, but the long-term effect of HAART on viral load remains unclear. In the Multicenter AIDS Cohort Study and the Women's Interagency HIV Study, 918 HIV-1-infected men and women who were not using antiretroviral therapy were followed for a median of 5.8 years between 1996 and 2005. Follow-up yielded 3,629 person-years of observation, during which 286 (31{\%}) of the participants initiated HAART. A marginal structural left-censored linear model for semiannual repeated assessments of viral load showed a 1.9 log10 decrease in viral load after HAART initiation as compared with nonuse (95{\%} confidence interval: 1.7, 2.2), which remained stable over the course of follow-up but was stronger among men (interaction p < 0.001). This association was attenuated by 10{\%} when the authors ignored the left-censoring of viral load measurements (which comprised 20{\%} of measurements (1,420/7,258)) and attenuated by 57{\%} when the authors adjusted for time-varying covariates in a standard fashion rather than using the marginal structural model. In conclusion, the clinically important protective effect of HAART on dampening viral load appears to be rapid, present at CD4 cell counts greater than 350 cells/mm3, and sustained beyond 6 years.",
keywords = "Acquired immunodeficiency syndrome, Antiretroviral therapy, highly active, Bias (epidemiology), Causality, Confounding factors (epidemiology), HIV-1, Viral load",
author = "Cole, {Stephen R.} and Hern{\'a}n, {Miguel A.} and Kathryn Anastos and Jamieson, {Beth D.} and Robins, {James M.}",
year = "2007",
month = "6",
doi = "10.1093/aje/kwm047",
language = "English (US)",
volume = "166",
pages = "219--227",
journal = "American Journal of Epidemiology",
issn = "0002-9262",
publisher = "Oxford University Press",
number = "2",

}

TY - JOUR

T1 - Determining the effect of highly active antiretroviral therapy on changes in human immunodeficiency virus type 1 RNA viral load using a marginal structural left-censored mean model

AU - Cole, Stephen R.

AU - Hernán, Miguel A.

AU - Anastos, Kathryn

AU - Jamieson, Beth D.

AU - Robins, James M.

PY - 2007/6

Y1 - 2007/6

N2 - Highly active antiretroviral therapy (HAART) dramatically reduces the load of circulating human immunodeficiency virus type 1 (HIV-1) by blocking replication at multiple points in the viral life cycle, but the long-term effect of HAART on viral load remains unclear. In the Multicenter AIDS Cohort Study and the Women's Interagency HIV Study, 918 HIV-1-infected men and women who were not using antiretroviral therapy were followed for a median of 5.8 years between 1996 and 2005. Follow-up yielded 3,629 person-years of observation, during which 286 (31%) of the participants initiated HAART. A marginal structural left-censored linear model for semiannual repeated assessments of viral load showed a 1.9 log10 decrease in viral load after HAART initiation as compared with nonuse (95% confidence interval: 1.7, 2.2), which remained stable over the course of follow-up but was stronger among men (interaction p < 0.001). This association was attenuated by 10% when the authors ignored the left-censoring of viral load measurements (which comprised 20% of measurements (1,420/7,258)) and attenuated by 57% when the authors adjusted for time-varying covariates in a standard fashion rather than using the marginal structural model. In conclusion, the clinically important protective effect of HAART on dampening viral load appears to be rapid, present at CD4 cell counts greater than 350 cells/mm3, and sustained beyond 6 years.

AB - Highly active antiretroviral therapy (HAART) dramatically reduces the load of circulating human immunodeficiency virus type 1 (HIV-1) by blocking replication at multiple points in the viral life cycle, but the long-term effect of HAART on viral load remains unclear. In the Multicenter AIDS Cohort Study and the Women's Interagency HIV Study, 918 HIV-1-infected men and women who were not using antiretroviral therapy were followed for a median of 5.8 years between 1996 and 2005. Follow-up yielded 3,629 person-years of observation, during which 286 (31%) of the participants initiated HAART. A marginal structural left-censored linear model for semiannual repeated assessments of viral load showed a 1.9 log10 decrease in viral load after HAART initiation as compared with nonuse (95% confidence interval: 1.7, 2.2), which remained stable over the course of follow-up but was stronger among men (interaction p < 0.001). This association was attenuated by 10% when the authors ignored the left-censoring of viral load measurements (which comprised 20% of measurements (1,420/7,258)) and attenuated by 57% when the authors adjusted for time-varying covariates in a standard fashion rather than using the marginal structural model. In conclusion, the clinically important protective effect of HAART on dampening viral load appears to be rapid, present at CD4 cell counts greater than 350 cells/mm3, and sustained beyond 6 years.

KW - Acquired immunodeficiency syndrome

KW - Antiretroviral therapy, highly active

KW - Bias (epidemiology)

KW - Causality

KW - Confounding factors (epidemiology)

KW - HIV-1

KW - Viral load

UR - http://www.scopus.com/inward/record.url?scp=34547604847&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547604847&partnerID=8YFLogxK

U2 - 10.1093/aje/kwm047

DO - 10.1093/aje/kwm047

M3 - Article

VL - 166

SP - 219

EP - 227

JO - American Journal of Epidemiology

JF - American Journal of Epidemiology

SN - 0002-9262

IS - 2

ER -